✨ Your Portfolio is fetched and updated from zerodha.
Nano Miscellaneous

Biogen Pharmachem Industries Ltd.

BIOGEN

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹75 Cr.
P/E
61.76

Biogen Pharmachem Industries Ltd.

  • Biogen Pharmachem
  • Filtra Consultants
  • Dhanalaxmi Roto Spin

FAQs on Biogen Pharmachem Industries Ltd. Shareprice

Biogen Pharmachem has given lower returns compared to its competitors.
Biogen Pharmachem has grown at ~3.16% over the last 2yrs while peers have grown at a median rate of 17.08%

Biogen Pharmachem is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Biogen Pharmachem is 61.76, while 3 year average PE is 58.85.
Also latest EV/EBITDA of Biogen Pharmachem is 44.64 while 3yr average is 211.

View FAQ's On Business

Growth Table

  • Biogen Pharmachem Industries Ltd.
  • Filtra Consultants
  • Dhanalaxmi Roto Spin

Balance Sheet

  • Biogen Pharmachem Industries Ltd.
  • Filtra Consultants
  • Dhanalaxmi Roto Spin

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Biogen Pharmachem Industries Ltd.
  • Filtra Consultants
  • Dhanalaxmi Roto Spin

Cash Flow

  • Biogen Pharmachem Industries Ltd.
  • Filtra Consultants
  • Dhanalaxmi Roto Spin

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Biogen Pharmachem Industries Ltd.
  • Filtra Consultants
  • Dhanalaxmi Roto Spin

Quarterly Results

  • Biogen Pharmachem Industries Ltd.
  • Filtra Consultants
  • Dhanalaxmi Roto Spin

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Biogen Pharmachem Industries Ltd. Financials

Biogen Pharmachem balance sheet is weak and might have solvency issues

The net debt of Biogen Pharmachem is decreasing.
Latest net debt of Biogen Pharmachem is -₹3.98 Crs as of Mar-25.
This is less than Mar-24 when it was -₹0.03 Crs.

The profit is oscillating.
The profit of Biogen Pharmachem is ₹1.21 Crs for TTM, -₹0.29 Crs for Mar 2025 and ₹1.93 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Biogen Pharmachem latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech